Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nurix Therapeutics (NRIX)
NASDAQ:NRIX
NRIX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.91 - $29.56
Previous CloseN/A
Volume302.00K
Average Volume (3M)684.89K
Market Cap
$1.29B
Enterprise Value$1.15B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.56
Next Earnings
Apr 09, 2025EPS Estimate
-0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.89
Shares Outstanding75,886,820
10 Day Avg. Volume674,054
30 Day Avg. Volume684,893
Standard Deviation0.23
R-Squared0.20
Alpha-0.00392
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)24.14
Price to Cash Flow (P/CF)-6.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit21.13
Enterprise Value/Ebitda-5.86
Forecast
1Y Price Target
$32.46Price Target Upside90.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
---
Nurix Therapeutics News
PremiumCompany Announcements
Nurix Therapeutics Faces Financial Risks Amid Supreme Court Regulatory ShiftPremiumCompany Announcements
Nurix Therapeutics Reports Solid Progress and Strong Pipeline---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsNRIX reiterated plans to commence clinical trials for NX-5948 with a path for accelerated approval.
Financial HealthThe company has significant cash reserves, which provide a financial runway for continued research and development efforts.
Bears Say
Risks And ChallengesFailure to obtain timely approval for pipeline candidates, particularly NX-2127 and NX-5948, is a risk.
---
Ownership Overview
4.87% Insiders
27.21% Mutual Funds
6.13% Other Institutional Investors
45.60% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NRIX FAQ
What was Nurix Therapeutics’s price range in the past 12 months?
Nurix Therapeutics lowest stock price was $9.91 and its highest was $29.56 in the past 12 months.
What is Nurix Therapeutics’s market cap?
Nurix Therapeutics’s market cap is $1.29B.
When is Nurix Therapeutics’s upcoming earnings report date?
Nurix Therapeutics’s upcoming earnings report date is Apr 09, 2025 which is in 46 days.
How were Nurix Therapeutics’s earnings last quarter?
Nurix Therapeutics released its earnings results on Jan 28, 2025. The company reported -$0.75 earnings per share for the quarter, missing the consensus estimate of -$0.686 by -$0.064.
Is Nurix Therapeutics overvalued?
According to Wall Street analysts Nurix Therapeutics’s price is currently Undervalued.
Does Nurix Therapeutics pay dividends?
Nurix Therapeutics does not currently pay dividends.
What is Nurix Therapeutics’s EPS estimate?
Nurix Therapeutics’s EPS estimate is -0.76.
How many shares outstanding does Nurix Therapeutics have?
Nurix Therapeutics has 75,886,820 shares outstanding.
What happened to Nurix Therapeutics’s price movement after its last earnings report?
Nurix Therapeutics reported an EPS of -$0.75 in its last earnings report, missing expectations of -$0.686. Following the earnings report the stock price went up 0.46%.
Which hedge fund is a major shareholder of Nurix Therapeutics?
Currently, no hedge funds are holding shares in NRIX
---
Nurix Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.46 (90.49% Upside)
$32.46 (90.49% Upside)
Blogger Sentiment
Bullish
NRIX Sentiment 75%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 686.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
68.88%
12-Months-Change
Fundamentals
Return on Equity
-53.22%
Trailing 12-Months
Asset Growth
85.28%
Trailing 12-Months
Company Description
Nurix Therapeutics
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
---
NRIX Stock 12 Month Forecast
Average Price Target
$32.46
▲(90.49% Upside)
Technical Analysis
Fate Therapeutics
―
Karyopharm Therapeutics
―
CytomX Therapeutics
―
Rhythm Pharmaceuticals
―
Arvinas Holding Company
―
Best Analysts Covering NRIX
1 Year
1 Year Success Rate
7/9 ratings generated profit
1 Year Average Return
+93.74%
reiterated a buy rating 4 months ago
Copying Derek Archila's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +93.74% per trade.
---